NASDAQ · PEPG
Healthcare · Biotechnology
$2.46
Down-$0.02 (-0.81%)
Updated Nov 4, 2026, 8:57 PM
SID Score
4.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · PEPG
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 3, 2026
PEPG closed at $2.46 after 21 trading sessions, up 6.49% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 3, 2026 | $2.36 | $2.485 | $2.36 | $2.46 | 615.35K |
| Nov 2, 2026 | $2.39 | $2.4672 | $2.305 | $2.35 | 565.92K |
| Oct 30, 2026 | $2.40 | $2.405 | $2.22 | $2.36 | 1.13M |
| Oct 29, 2026 | $2.54 | $2.62 | $2.40 | $2.41 | 770.04K |
| Oct 28, 2026 | $2.58 | $2.64 | $2.485 | $2.53 | 767.84K |
| Oct 27, 2026 | $2.49 | $2.62 | $2.47 | $2.60 | 1.33M |
| Oct 26, 2026 | $2.51 | $2.675 | $2.4603 | $2.49 | 906.89K |
| Oct 23, 2026 | $2.68 | $2.80 | $2.44 | $2.52 | 1.16M |
| Oct 22, 2026 | $2.71 | $2.83 | $2.65 | $2.70 | 1.04M |
| Oct 21, 2026 | $2.89 | $2.9899 | $2.72 | $2.72 | 1.17M |
| Oct 20, 2026 | $2.66 | $2.94 | $2.62 | $2.87 | 2.77M |
| Oct 19, 2026 | $2.55 | $2.73 | $2.495 | $2.70 | 1.08M |
| Oct 16, 2026 | $2.56 | $2.69 | $2.50 | $2.60 | 1.2M |
| Oct 15, 2026 | $2.30 | $2.60 | $2.30 | $2.53 | 764.2K |
| Oct 14, 2026 | $2.44 | $2.49 | $2.26 | $2.32 | 917.35K |
| Oct 13, 2026 | $2.48 | $2.60 | $2.41 | $2.50 | 1.22M |
| Oct 12, 2026 | $2.61 | $2.61 | $2.48 | $2.49 | 315.77K |
| Oct 9, 2026 | $2.39 | $2.65 | $2.39 | $2.62 | 603.87K |
| Oct 8, 2026 | $2.38 | $2.4471 | $2.28 | $2.38 | 845.1K |
| Oct 7, 2026 | $2.31 | $2.48 | $2.275 | $2.40 | 642.78K |
| Oct 6, 2026 | $2.38 | $2.385 | $2.26 | $2.31 | 590.17K |
The latest Smart Investors Daily articles mentioning PEPG.
Company
Market Activity
Research & News
PEPG research
Company profile and research snapshot.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 9, 2026 | HC Wainwright & Co. | Buy | — |
| Jun 16, 2026 | Craig-Hallum | Buy | — |
| May 13, 2026 | Wedbush | Outperform | — |
| Apr 1, 2026 | Wedbush | Outperform | — |
| Mar 31, 2026 | Wedbush | Outperform | — |
No generated briefing is available yet.
Benzinga · Sep 17, 2026
Gainers Alaunos Therapeutics (NASDAQ:TCRT) shares moved upwards by 30.0% to $2.08 during Thursday's after-market session. The company's market cap stands at $3.2 million. cbdMD (AMEX:YCBD) stock increased by
Benzinga · Sep 9, 2026
HC Wainwright & Co. analyst Ananda Ghosh reiterates PepGen (NASDAQ:PEPG) with a Buy and maintains $20 price target.
Benzinga · Aug 6, 2026
PepGen (NASDAQ:PEPG) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.29) by 10.34 percent. This is a 62.86 percent increase over losses of $(0.70) per share from the same
Benzinga · Aug 6, 2026
Independent Data and Safety Monitoring Board (DSMB) has recommended advancing the ongoing Phase 2 FREEDOM2-DM1 study evaluating PGN-EDODM1 in participants with myotonic dystrophy type 1 (DM1) into the third and highest
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning PEPG.
